Despite the recent company's efforts to reduce its debit, from a technical point of view, I would be neutral with Teva
until we will see a cross-over between slow 200d and fast 50d moving average on a daily chart
pattern. For those who are aggressives MACD
is still positive but keep in mind the resistence at 19.33 first and 20 after. Exhaustion gap betweeen 16 and 18 has been filled. Personally I see such movement as a prize for what the new CEO
has done to reduce the impact of debit in short and mid term. Still 2018 will be critical to conferm that what has been undertaken is going toward in the right direction.